Nasus Pharma, an Israeli biopharmaceutical company announced on Monday that one of its products, Taffix, has shown 100% effectiveness in blocking the highly infective Delta variant following a study conducted with the Health Ministry.
According to a press release, the data analysis showed that "the gel layer produced by Taffix powder after administration of a tissue culture infectious dose of the virus, effectively blocked 100% [of the variant]."
Follow Israel Hayom on Facebook and Twitter
"This in addition to recently announced efficacy of Taffix under the same conditions against two additional variants : Alpha ("British") and Beta ("South African") variants as demonstrated by qt PCR testing of cells incubated with Taffix inoculated with the viruses," the company announced in a statement.
"Importantly these results are consistent with real life clinical experience with Taffix where the risk of contracting COVID was reduced by 78% following a "super spreader 'event. These consistent results across multiple virus strains prove the robust non-specific activity against the transmission of multiple respiratory viruses," Dr. Dalia Megiddo, the CEO of Nasus Pharma, said. "The study's results reconfirm the versatility of our technology against various respiratory viruses including SARS-CoV-2 and its new variants and Taffix's potential as an important additional layer of protection against infection," she continued.
Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute situations such as opioid overdose and anaphylactic shock.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
